Why I Sold My Invitae Stock

Published by
The Street

By Maxx Chatsko The genetic testing company has been unprofitable as it spent heavily (but that’s only part of the story). For years I have detested the growth-at-all-costs business models followed by emerging growth companies. They work – until one day (or quarterly update) they don’t. All it takes is one disappointing revenue growth rate or downward revision in guidance for Wall Street analysts to issue sharply lower price targets. The little guy is usually the one that ends up getting hurt. That means you, dear reader. One of my go-to examples over the years was genetic testing company Invi…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street